Shilpa Gupta· @shilpaonc · X·· 21 小时前评分70
正文 · 原文
#ESMO26 Very thoughtful and balanced discussion of VOLGA trial by @MichvdHeijden , putting EV-D in perspective with EV-303/B15 on efficacy & safety.
Adding treme = more tox, no efficacy/OS gain.
Less is more!
Takeaway for next steps:
response-adapted adjuvant therapy?
@myESMO @tompowles1 @brian_rini @Uromigos
42 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源:Shilpa Gupta · x.com
